Lv12
20 积分 2024-11-18 加入
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1天前
已完结
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
3个月前
已完结
HR+/HER-2-早期乳腺癌复发风险与临床管理专家共识（2025版）
3个月前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
8个月前
已完结
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
10个月前
已完结
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer
10个月前
已完结
皖公网安备34019202002308
